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ABSTRACT
Although the exact burden of disease caused by methicillin-resistant Staphylococcus aureus (MRSA)
remains largely unknown, most experts agree that MRSA infections are an important clinical and public
health problem. Thousands of reports have been published during the last four decades concerning
epidemiological and microbiological aspects of MRSA, but uncertainty remains about the best approach
to prevent and control this worldwide plague, especially endemic MRSA. Epidemiological methods,
e.g., risk scores for targeted screening upon admission, rapid molecular tests and pre-emptive isolation
of high-risk patients, new decontamination regimens and restriction of certain antibiotic classes, are all
promising approaches that may decrease MRSA cross-transmission; however, further evidence is
needed before these strategies can be implemented on a wide scale. Control of community MRSA is an
additional challenge for the future, requiring improved surveillance and contact tracing, as well as
education and treatment of both infected cases and colonised contacts. This review summarises recent
advances and studies that address these issues. Overall, it seems that there is no level of MRSA
prevalence for which active control measures are no longer warranted.
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INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA)
is a versatile bacterial pathogen, combining viru-
lence, antibiotic resistance and survival fitness.
Clonal spread is facilitated by cross-transmission
via the hands of healthcare workers and the
selection pressure exerted by broad-spectrum
antibiotic treatment. MRSA infections often re-
quire systemic antibiotic therapy and are an
important healthcare burden, since they increase
treatment costs and patient morbidity [1]. Under
certain circumstances, MRSA may even contrib-
ute to excess mortality. The magnitude of this
effect depends on the adequacy of treatment and
the patient population studied. In critically-ill
patients, microbiologically inadequate therapy for
severe MRSA infections may increase the likeli-
hood of death [2]. Conversely, in less severely ill
patients, inadequate empirical treatment may not
be associated with a greatly increased risk of
death after adjusting for independent predictors
for mortality [3].
Although the exact burden of disease caused by
MRSA remains largely unknown, most experts
agree that MRSA infections are an important
public health problem that increases the overall
burden of infectious disease in a country [4]. This
can be best illustrated by the example of the UK,
where death certificates are surveyed systematic-
ally to determine the proportion of MRSA-related
deaths. The most recently published surveillance
report revealed that the annual number of death
certificates with the mention of MRSA as an
underlying cause had increased from 15 to 360
over a decade (Fig. 1) [5].
Although MRSA causes great concern among
patients and healthcare professionals, the chances
of successful control have been questioned repeat-
edly for various reasons, including the recent
emergence of community MRSA, the increasing
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reservoir of nosocomial MRSA, the impossibility
of eradicating endemic MRSA, and the significant
costs and disruption in patient care associated
with active surveillance and control measures [6].
In particular, the most efficient strategy to control
endemic MRSA remains controversial [7,8]. This
ongoing debate prompts questions concerning
evidence-based interventions and innovative
approaches that could improve the control of
endemic MRSA and reduce its clinical impact.
The purpose of the present review is to summa-
rise recent advances and studies that have
addressed these issues.
PREVENTION STRATEGIES FOR
ENDEMIC, HEALTHCARE-
ASSOCIATED MRSA
Control of endemic MRSA relies on several
complementary control strategies that are men-
tioned frequently in the infection control litera-
ture (Fig. 2). First, early detection of
asymptomatic MRSA carriers may allow rapid
contact isolation and decrease the likelihood of
spread. Second, reduction of MRSA carriage
with topical treatment and antiseptic body wash-
ing, as well as thorough environmental cleaning,
may reduce the MRSA reservoir. Third, im-
proved compliance with hand hygiene and
standard precautions may decrease transmission.
Finally, it has been postulated repeatedly that
reduction of antibiotic selection pressure may
have a beneficial effect on MRSA acquisition and
carriage rates. This review has been structured to
consider these basic approaches to the control of
MRSA.
ACTIVE SURVEILLANCE AND
ISOLATION
For most patients, MRSA is merely a colonising
organism and can only be detected through active
screening. Unknown MRSA carriers constitute the
main reservoir and source of further spread
following hospitalisation. Several recent studies
have shown the importance of surveillance cul-
tures of patients in order to prevent MRSA
transmission [8-11]. Although the most efficient
MRSA screening strategy depends on the local
situation, and is still a matter of debate, many
affected acute-care hospitals in western and nor-
thern Europe have implemented targeted screen-
ing policies for patient groups at high risk of
MRSA carriage and infection, and apply specific
preventive measures (contact isolation) to identi-
fied carriers. In an unpublished survey of 68
infectious disease experts from different parts of
Europe, 85% indicated that their hospital had
implemented some type of patient screening
policy.
Recent modelling studies have suggested that a
policy of screening newly admitted patients for
MRSA, coupled with rapid and effective isolation
and treatment, could make a major contribution
Fig. 1. Burden of methicillin-resist-
ant Staphylococcus aureus (MRSA) in
the UK. Number of death certificates
with methicillin-sensitive S. aureus
(MSSA) or MRSA as the underlying
cause, UK (1993–2004). Adapted
from [5].
Fig. 2. Standard approaches for the control of endemic
methicillin-resistant Staphylococcus aureus.
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to controlling the spread of MRSA [12,13]. Boots-
ma et al. [13] suggested that a full ‘search-and-
destroy’ policy could reduce high MRSA ende-
micity to a prevalence of <1% within 6–12 years.
The most important components of this control
strategy involved contact tracing of identified
MRSA patients, screening of high-risk patients
upon admission, increased adherence to standard
hygiene and isolation precautions, and the use of
rapid diagnostic tests. Small additional effects
were estimated for screening of healthcare work-
ers, use of MRSA decolonisation regimens and
closure of wards following identification of large
clusters of MRSA patients [13].
In contrast to these modelling studies, Cepeda
et al. [7] were unable to confirm the efficacy of
patient isolation or cohorting in preventing
spread of MRSA in two UK intensive care units
(ICUs). Possible reasons for the failure of these
interventions were as follows: there was a high
colonisation pressure upon admission (up to 30%
of screened patients were MRSA-positive); only
those patients who stayed for >2 days were
screened (50% of the overall population); no
rapid MRSA screening technique, or pre-emptive
isolation while awaiting culture results, was used;
only nurse cohorting was performed, without
cohorting of other groups of healthcare workers;
and hand hygiene compliance was very low
(20%).
PREDICTION OF PREVIOUSLY
UNKNOWN MRSA CARRIAGE UPON
ADMISSION
Although risk-factors for nosocomial MRSA
acquisition have been described in numerous
studies, few investigators have developed practi-
cal tools to identify previously unknown MRSA
carriage upon hospital admission [14,15]. In the
study by Troillet et al. [14], three patient charac-
teristics (diabetes, antibiotic treatment within the
previous 6 months, and exposure to a healthcare
facility within the past year) predicted MRSA
carriage with a high sensitivity. The study by
Lucet et al. [15] confirmed the importance of
previous healthcare exposure in identifying
MRSA carriers upon admission to different ICUs
in the Paris region. Two recent studies examining
MRSA bacteraemia at the time of hospital admis-
sion identified previous hospitalisation, receipt of
antibiotics, the presence of indwelling catheters,
diabetes mellitus and residence in a nursing home
as independent risk-factors [16,17].
In 2003, a prospective, case-controlled, on-
admission screening study was conducted with
all adult inpatients admitted to Geneva Univer-
sity Hospitals in order to determine the preval-
ence and risk profile of patients with previously
unknown carriage of MRSA upon hospital admis-
sion [18]. Multivariate conditional logistic regres-
sion for datasets, matched 1:4, was performed in
order to identify the risk profile of newly identi-
fied MRSA carriers. Overall, 399 of 12 072
screened admissions (a prevalence of 3.3%) were
MRSA-positive. MRSA carriage was newly iden-
tified in 204 individuals (a prevalence of 1.7%).
Nine independent risk-factors were identified for
MRSA carriage upon admission (adjusted OR):
male gender (1.9); age >75 years (2.0); receipt of
fluoroquinolones (2.7), cephalosporins (2.1)
or carbapenems (3.2) during the previous
6 months; hospitalisation (1.9) or intravenous
therapy (1.7) during the previous 12 months;
urinary catheter upon admission (2.0); and intra-
hospital transfer (2.4).
Based on the results of a simplified multiva-
riate analysis (n = 594), and by adding points
assigned to four easily retrievable variables (age
>80 years, hospitalisation within the previous
12 months, antibiotic use within the previous
6 months, and the presence of a urinary catheter
upon admission), a practical risk score was
calculated for patients admitted to the acute-care
sector [18]. The probability of MRSA carriage
was 8% in patients with 0 points, 18% in those
with 1 point, 31% in those with 2 points, and
57% in those with ‡3 points (Fig. 3). In the
presence of any of these risk-factors, this model
Fig. 3. Risk score model to identify previously unknown
carriage of methicillin-resistant Staphylococcus aureus upon
admission to the acute-care sector of Geneva University
Hospitals (2003). Adapted from [18].
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would have identified 84% of patients (100 ⁄ 119),
but would have required the screening of 64% of
the patients admitted. An on-admission study
from the USA validated this risk index, demon-
strating almost identical results (sensitivity, 84%;
number of patients to be screened, 65%) [19].
Both studies concluded that the prevalence of
previously unknown MRSA carriers upon
admission is high in settings with endemic
MRSA, and that applying a risk score to newly
admitted patients with an intermediate or high
probability of MRSA carriage could form part of
a more effective control strategy.
For the geriatric setting, an independent risk
index was calculated and validated with a separ-
ate dataset generated during 2001 [20]. The
prevalence of MRSA carriage upon admission to
the geriatric hospital in Geneva increased from
7.3% (53 ⁄ 724 patients) in 2001 to 8.7% (78 ⁄ 897) in
2003, with a corresponding prevalence of un-
known MRSA carriers of 4.6% and 5.8%, respect-
ively. Three variables were associated
independently with previously unknown MRSA
carriage: recent antibiotic treatment (adjusted
OR 2.3); intra-hospital transfer (2.5); and hospi-
talisation during the past 2 years (2.7). In the
validation cohort, the probability of MRSA car-
riage increased across risk scores: 0 points, 4%
prevalence (6 ⁄ 146); 1 point, 15% (21 ⁄ 136); and ‡2
points, 31% (21 ⁄ 68; p <0.001). This risk score
showed good discrimination and calibration in
both groups.
RAPID SCREENING WITH
MOLECULAR TESTS
Application of rapid MRSA screening tools may
improve patient outcomes by decreasing MRSA
transmission and infection rates, and by direct-
ing the choice of antibiotic agents (e.g., vanco-
mycin) for antibiotic prophylaxis and treatment.
Previous studies concerning rapid MRSA screen-
ing tests did not examine their effect on infection
rates, and assessed only the time of specimen
processing, without taking into account transport
of specimens and the delay between admission
and screening [21,22]. Therefore, an interven-
tional cohort study was conducted to assess
whether a new molecular technique enabling
early detection of MRSA carriage can decrease
the time between ICU admission and identifica-
tion of previously unknown MRSA carriers, and
whether this new method has an effect on ICU-
acquired MRSA infections [23]. All patients
admitted for >24 h to two ICUs were screened
systematically upon admission by multiplex
immunocapture-coupled PCR [24]. This test
allows quick diagnosis of MRSA carriage
through detection of the mecA gene (in S. aureus
and Staphylococcus epidermidis). Median time to
notification decreased from 87 h to 21 h in the
surgical ICU (p <0.05), and from 106 h to 23 h in
the medical ICU (p <0.05). No effect on MRSA
prevalence was observed in the surgical ICU,
although a large number of unnecessary pre-
emptive isolation-days could be saved by using
the rapid test. A substantial decrease in MRSA
infections was seen in the medical ICU after
increasing the compliance with on-admission
screening and implementation of a strategy
linking the rapid test to pre-emptive isolation
and cohorting of MRSA patients [23] (Fig. 4).
PATIENT DECOLONISATION
Carriage of MRSA is an important risk-factor for
subsequent infection, and facilitates cross-trans-
mission. Based on these assumptions, several
intervention studies have been performed with
the aim of reducing the rates of MRSA infection
by eradicating MRSA carriage. In particular,
mupirocin nasal ointment has been used to
eradicate carriage because of its effectiveness,
safety and relatively low cost [25]. Although some
data suggest that mupirocin is effective in redu-
cing nasal carriage of S. aureus, a recent system-
atic review concluded that there is insufficient
evidence to support the use of topical or systemic
antimicrobial therapy for eradicating extra-nasal
MRSA carriage, except in well-defined outbreak
settings [26]. Results from a randomised, placebo-
controlled trial performed at our institution did
not support the hypothesis that routine use of
topical intra-nasal mupirocin for prevention of
MRSA infections is warranted for all MRSA
carriers [27], and also revealed that mupirocin
should not be used in patients presenting with
open sores or medical devices [27,28].
The exact role of stool colonisation by MRSA
is still a matter of debate. Two recent studies
have suggested that MRSA stool carriage is an
important reservoir and that topical decontam-
ination with oral vancomycin may have a bene-
ficial effect [29,30]. Clearly, more controlled
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studies are needed before this practice is widely
adopted.
Although many different topical skin decon-
tamination regimens are in use, the evidence
base for this practice remains weak. An inter-
vention study from the USA has shown that the
application of a chlorhexidine-based skin decon-
tamination regimen for critically-ill patients
resulted in decreased acquisition of MRSA, as
well as decreased skin and environmental con-
tamination with vancomycin-resistant enterococ-
ci [31]. This procedure also had an effect on
MRSA infection rates (M. Hayden, personal
communication).
ENVIRONMENTAL CONTROL
For more than two decades, infection control
focused on patients, rather than the patients’
environment, as the most important source of
nosocomial infection. This approach was based on
studies that failed to find reductions in the rates of
nosocomial infection after hospital units were
moved into new, clean accommodation [32].
However, there is a growing body of literature
emphasising that MRSA is ubiquitous in the
hospital environment of MRSA patients, and that
it can be cross-transmitted easily on the hands of
healthcare workers [33]. Therefore, appropriate
cleaning and disinfection procedures are essential
to decrease the microbial burden in the close
patient environment and to minimise the likeli-
hood of MRSA cross-infection. Recent provisional
data (16th European Congress for Clinical Micro-
biology and Infectious Diseases, abstracts P1333
and P1336) suggest that thorough patient and
environmental decontamination regimens may
help to decrease MRSA acquisition when used
in combination with other control measures.
HAND HYGIENE
MRSA mostly spreads from patient to patient via
the transiently colonised hands of healthcare
workers during patient contact or after handling
contaminated materials. Strict compliance with
standard precautions, e.g., hand disinfection,
could prevent most cases of cross-transmission
without any need for recognition of individual
MRSA carriers. Unfortunately, it has been shown
that the compliance of healthcare workers with
hand hygiene recommendations is poor [34].
Alcohol-based antiseptic agents at the bedside
have great potential for increasing compliance, as
they allow fast hand hygiene procedures during
patient care, achieve rapid microbial killing, and
may even improve the skin condition of the hands
of healthcare workers [35].
Several studies have shown that promotion of
alcohol-based hand rinses can improve compli-
ance and save money by reducing episodes of
cross-infection [36,37]. A report from Australia
has shown that improved MRSA control can be
achieved through promotion of alcohol-based
Fig. 4. Previously known carriage of methicillin-resistant
Staphylococcus aureus (MRSA) upon admission vs. intensive
care unit (ICU)-acquired MRSA infection. Shown are the
number of patients with previously known MRSA carriage
upon admission (MRSA colonisation pressure) and the
number of patients with ICU-acquired MRSA infections
(surgical and medical ICUs; Geneva University Hospitals;
January 2003 to August 2005). Lower panel, medical ICU:
The vertical line indicates the initiation of rapid on-
admission screening in November 2003. The dashed
vertical line indicates the initiation of pre-emptive isolation
for all patients in April 2004. Upper panel, surgical ICU:
The vertical line indicates the initiation of rapid MRSA
screening upon admission and the extension of pre-
emptive isolation in November 2003. Adapted from [23].
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hand hygiene (Fig. 5), which does not need to be
costly [38]. Large-scale public health interven-
tions, e.g., the recently launched WHO campaign
‘Clean care is safer care’, may contribute to a
decrease in MRSA infection rates [39].
ANTIBIOTIC RESTRICTION
Antibiotic selection pressure greatly facilitates
acquisition and persistent colonisation of MRSA
by decreasing colonisation resistance and eradi-
cating competing susceptible flora [40]. Fluoroqu-
inolones, in particular, tend to increase the
occurrence and persistence of multiresistant sta-
phylococci [41]. In an outbreak report from
Germany, thorough investigation of multiple
risk-factors showed that previous fluoroquino-
lone exposure was an independent risk-factor for
carriage of MRSA [42]. Moreover, in a prospective
cohort study, fluoroquinolone exposure was
found to predict prolonged MRSA carriage and
to decrease the likelihood of MRSA eradication
[28].
Despite these observational studies, the effect
of antibiotic control policies in the prevention of
nosocomial MRSA acquisition and cross-infection
remains uncertain. A systematic review has high-
lighted the weakness of much of the evidence
concerning this issue [43], since only one study
was considered adequate in assessing the effect of
an antibiotic control strategy on nosocomial
MRSA transmission. In that study, no effect on
MRSA occurrence was observed during a 7-year
period [44]. However, data from two recently
published intervention studies in France and the
USA suggest that restriction of fluoroquinolone
use may decrease MRSA rates [45,46]. Clearly,
other well-designed investigations are needed to
determine whether reductions in overuse of anti-
microbial agents and improvements in antimicro-
bial selection have a favourable effect on MRSA
rates.
NEW CHALLENGES AHEAD:
COMMUNITY MRSA
The scope of staphylococcal antibiotic resistance
is currently extending to more clinical settings
and to new patient populations. While antibiotic-
resistant S. aureus was once thought to be con-
fined to large hospitals, community outbreaks of
MRSA are now occurring in individuals without
traditional risk-factors for carriage of MRSA.
Although outpatients with a history of intraven-
ous drug use, nursing home residency or recent
hospitalisation appear to have a heightened risk
for MRSA carriage [18,47], a significant minority
of patients admitted with MRSA carriage do not
have such identifiable risk-factors.
The prevalence of community-associated (CA)
MRSA carriage in Europe remains largely un-
known, since few systematic studies have as-
sessed its epidemiology [48]. Determining the
epidemiology of CA-MRSA could help in the
development of control measures and in guiding
clinicians in the identification of patients at high
risk of CA-MRSA. Therefore, based on the previ-
ously described on-admission screening study
conducted in 2003 [18], an observational study
was conducted to determine the prevalence of
CA-MRSA upon hospital admission to our insti-
Fig. 5. Use of alcohol-based hand rubs (ACHRS) (upper
panel) and the frequency of clinical methicillin-resistant
Staphylococcus aureus isolates (lower panel); Austin Health
(840-bed University of Melbourne teaching hospital), 1999–
2004. Adapted with permission from [38].
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tution and to examine the characteristics of
patients carrying CA-MRSA [49]. The study
revealed: (i) a low prevalence of CA-MRSA upon
hospital admission (9 ⁄ 10 000 admissions); (ii) a
reservoir of asymptomatic carriers of exotoxin-
containing CA-MRSA strains; (iii) no readily
modifiable risk-factor for CA-MRSA acquisition;
and (iv) a high degree of molecular diversity of
CA-MRSA in the study population [49].
Since 2002, a CA-MRSA surveillance system
has been established in Geneva in order to ensure
adequate case investigation and contact tracing, to
estimate incidence and transmission patterns, and
to develop targeted prevention strategies. The
medical community and the two main microbio-
logy laboratories participate actively on a volun-
tary basis in the surveillance system [50]. Between
January 2002 and December 2004, 58 cases of CA-
MRSA were reported; 41 cases (71%) were infec-
ted and 17 (29%) were colonised. Abscesses and
furunculosis were the most common clinical
presentations. Seven cases were temporary resi-
dents who lived abroad, and 38 had travelled
abroad in the preceding 12 months. A total of 26
cases could be grouped into 13 distinct transmis-
sion clusters [50].
NOSOCOMIAL TRANSMISSION OF
CA-MRSA
CA-MRSA can spread easily within the healthcare
setting, especially in neonatal and paediatric
wards [51]. Several recent reports have described
measures to control nosocomial outbreaks of CA-
MRSA in neonatal units [52]. In a series of eight
post-partum women who were involved in a
nosocomial cluster of cases of Panton–Valentine
leukocidin-producing CA-MRSA causing mastitis,
cellulitis and surgical site infection, the outbreak
was terminated by screening and contact isolation
[53]. Another outbreak in a nursery in Norway,
caused by an unusual MRSA strain associated
with pustulosis in seven neonates, was halted by
stringent preventive measures, including closure
of the unit and an increased staffing level [54].
The identification of a cluster of seven prema-
ture neonates colonised with MRSA between
20 June and 29 July 2000 in Geneva prompted
an epidemiological investigation [55].
This revealed the first documented outbreak of
Panton–Valentine leukocidin-producing CA-
MRSA (ST5-MRSA-IV) in a European neonatal
ICU, which was paralleled by a small cluster of
MRSA cases caused by an endemic nosocomial
strain (ST228-MRSA-I). Active surveillance, con-
tact isolation and detailed molecular analysis
helped to elucidate and terminate this outbreak
after a period of 6 weeks. One infant involved in
the summer 2000 outbreak had persistent CA-
MRSA carriage, resulting in skin infection in a
sibling 4 years after the initial outbreak [55].
CONCLUSIONS
The exact burden of disease caused by MRSA
remains largely unknown, and there is still
contradictory evidence with respect to key ques-
tions concerning the most cost-effective methods
for control of endemic MRSA. Several well-con-
ducted studies from France, Germany, the UK
and the USA have illustrated this dilemma. Use of
epidemiological methods, e.g., risk scores for
targeted on-admission screening, rapid molecular
tests and pre-emptive isolation of high-risk
patients, new decontamination regimens and
restriction of certain antibiotic classes, provide
promising approaches towards decreasing MRSA
cross-transmission; however, further evidence is
needed to implement these strategies on a wide
scale. Control of community MRSA infections is
an additional challenge for the future, requiring
improved surveillance, contact tracing, education,
and treatment of both infected cases and colo-
nised contacts. Whatever the final outcome of the
ongoing debate concerning the most efficient way
to control endemic MRSA infections, health
authorities and policy-makers would be well-
advised to put stringent efforts and funds into
their control efforts. MRSA is a concern for
everyone, not just hospital epidemiologists and a
few opinion leaders [56].
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